Posted by Michael Wonder on 27 Feb 2023
PHARMAC shares the agenda items for the upcoming Rare Disorders Committee meeting
27 February 2023 - PHARMAC is creating visibility of what medicines are being considered that could impact the rare disorders community by sharing the agenda items for the upcoming Rare Disorders Advisory Committee meeting.
PHARMAC’s Chief Medical Officer, Dr David Hughes is pleased to have a number of applications for the clinical advisors to consider. “Three of the proposals are for spinal muscular atrophy – two are for wider eligibility groups for nusinersen sodium and risdiplam at other ages and stages of the condition.
